Limits...
Trial of specific antigen-mediated leukocyte adherence inhibition test in patients with chronic active hepatitis and hepatitis B carrier.

Oh YI, Song SH, Kim WH, Cho KH, An JK, Ahn DS - Korean J. Intern. Med. (1986)

View Article: PubMed Central - PubMed

ABSTRACT

In the pathogenesis of chronic active hepatitis, the importance of cell mediated immunity (CMI) has been emphasized. Leukocyte adherence inhibition (LAI) assay, which is one of the methods for analysis of the reaction of CMI, has been used to analysie the CMI of cancer patients.

The authors tried the specific antigen-mediated LAI assay in 40 patients with chronic active hepatitis, 19 patients carriers of hepatitis B virus, and in the 5 persons who have no anti-HBs in spite of receiving vaccination against HBV, and these were compared with 7 normal control subjects who had been exposed to hepatitis B virus previously.

The NAI was 52.4±14 (mean ± standard deviation) in 7 normal control subjects who had been exposed to hepatitis B virus previously.

The NAI was 20.6 ± 11 (mean ± standard deviation) in 40 patients with chronic active hepatitis. The value was significantly lower than that of the normal control group (P<0.001).

The NAI was 49.7±17.8 (mean ± standard deviation) in 19 patients carriers of hepatitis B virus. The value was not significantly different from that of the normal control group (P>0.05).

The NAI was 25.1±11 (mean ± standard deviation) in 5 persons who have no anti-HBs in spite of receiving vaccination against HBV. The value was significantly lower than that of the normal control group (P<0.05).

In patients with chronic active hepatitis and hepatitis B virus carriers, we checked the LAI assay serially. The value of NAI was increased according to the improvement of clinical symptoms and normalization of transaminase, but the value of NAI was decreased according to the worsening of clinical symptoms and elevation of transaminase.

In patients with chronic active hepatitis and hepatitis B virus carriers, we checked the LAI assay serially. The value of NAI was increased according to the improvement of clinical symptoms and normalization of transaminase, but the value of NAI was decreased according to the worsening of clinical symptoms and elevation of transaminase.

Show MeSH
Comparison of the value of nonadherent index (NAI) among groups.Group I–IV: See Table 1
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4536717&req=5

f1-kjim-1-2-158-5: Comparison of the value of nonadherent index (NAI) among groups.Group I–IV: See Table 1

Mentions: In patients with chronic active hepatitis and hepatitis B carriers, we did the LAI assay serially. The value of NAI increased according to the improvement of clinical symptoms and normalization of the transaminase, but the value of NAI decreased according to the worsening of clinical symptoms and elevation of transaminase (Table 6, Fig. 1).


Trial of specific antigen-mediated leukocyte adherence inhibition test in patients with chronic active hepatitis and hepatitis B carrier.

Oh YI, Song SH, Kim WH, Cho KH, An JK, Ahn DS - Korean J. Intern. Med. (1986)

Comparison of the value of nonadherent index (NAI) among groups.Group I–IV: See Table 1
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4536717&req=5

f1-kjim-1-2-158-5: Comparison of the value of nonadherent index (NAI) among groups.Group I–IV: See Table 1
Mentions: In patients with chronic active hepatitis and hepatitis B carriers, we did the LAI assay serially. The value of NAI increased according to the improvement of clinical symptoms and normalization of the transaminase, but the value of NAI decreased according to the worsening of clinical symptoms and elevation of transaminase (Table 6, Fig. 1).

View Article: PubMed Central - PubMed

ABSTRACT

In the pathogenesis of chronic active hepatitis, the importance of cell mediated immunity (CMI) has been emphasized. Leukocyte adherence inhibition (LAI) assay, which is one of the methods for analysis of the reaction of CMI, has been used to analysie the CMI of cancer patients.

The authors tried the specific antigen-mediated LAI assay in 40 patients with chronic active hepatitis, 19 patients carriers of hepatitis B virus, and in the 5 persons who have no anti-HBs in spite of receiving vaccination against HBV, and these were compared with 7 normal control subjects who had been exposed to hepatitis B virus previously.

The NAI was 52.4±14 (mean ± standard deviation) in 7 normal control subjects who had been exposed to hepatitis B virus previously.

The NAI was 20.6 ± 11 (mean ± standard deviation) in 40 patients with chronic active hepatitis. The value was significantly lower than that of the normal control group (P<0.001).

The NAI was 49.7±17.8 (mean ± standard deviation) in 19 patients carriers of hepatitis B virus. The value was not significantly different from that of the normal control group (P>0.05).

The NAI was 25.1±11 (mean ± standard deviation) in 5 persons who have no anti-HBs in spite of receiving vaccination against HBV. The value was significantly lower than that of the normal control group (P<0.05).

In patients with chronic active hepatitis and hepatitis B virus carriers, we checked the LAI assay serially. The value of NAI was increased according to the improvement of clinical symptoms and normalization of transaminase, but the value of NAI was decreased according to the worsening of clinical symptoms and elevation of transaminase.

In patients with chronic active hepatitis and hepatitis B virus carriers, we checked the LAI assay serially. The value of NAI was increased according to the improvement of clinical symptoms and normalization of transaminase, but the value of NAI was decreased according to the worsening of clinical symptoms and elevation of transaminase.

Show MeSH